[1]裴金仙,陈天狮,任巧晶,等.JAK2/STAT3通路在HBV相关肝细胞癌中表达及机制研究[J].医学信息,2022,35(24):59-62.[doi:10.3969/j.issn.1006-1959.2022.24.012]
　PEI Jin-xian,CHEN Tian-shi,REN Qiao-jing,et al.The Expression and Mechanism of JAK2/STAT3 Pathway in HBV-related Hepatocellular Carcinoma[J].Journal of Medical Information,2022,35(24):59-62.[doi:10.3969/j.issn.1006-1959.2022.24.012]
点击复制

JAK2/STAT3通路在HBV相关肝细胞癌中表达及机制研究()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
35卷
期数:
2022年24期
页码:
59-62
栏目:
论著
出版日期:
2022-12-15

文章信息/Info

Title:
The Expression and Mechanism of JAK2/STAT3 Pathway in HBV-related Hepatocellular Carcinoma
文章编号:
1006-1959（2022）24-0059-04
作者:
裴金仙; 陈天狮; 任巧晶; 等
（山西省人民医院感染性疾病科，山西 太原 030012）
Author(s):
PEI Jin-xian; CHEN Tian-shi; REN Qiao-jing; et al.
(Department of Infectious Diseases,Shanxi Province People’s Hospital,Taiyuan 030012,Shanxi,China)
关键词:
HBV; 肝细胞癌; JAK2; STAT3; HBx
Keywords:
HBV; Hepatocellular carcinoma; JAK2; STAT3; HBx
分类号:
R735.7；R512.6+2
DOI:
10.3969/j.issn.1006-1959.2022.24.012
文献标志码:
A
摘要:
目的 探讨JAK2/STAT3通路在HBV相关肝细胞癌中的表达及机制研究。方法 选取2019年2月-2021年4月山西省人民医院诊治的HBV相关肝细胞癌患者和非HBV相关肝细胞癌患者各15例。采用Western blot法检测癌组织及癌旁组织JAK2、p-JAK2、STAT3和p-STAT3蛋白的表达，进一步检测稳定表达HBx的HepG2细胞株JAK2、p-JAK2、STAT3和p-STAT3蛋白的表达。结果 HBV-HCC组和HCC组癌组织中JAK2、p-JAK2、STAT3、p-STAT3蛋白表达水平均高于癌旁组织，差异有统计学意义（P＜0.05）；HBV-HCC组较HCC组癌组织中JAK2、STAT3蛋白表达升高，差异无统计学意义（P＞0.05），但p-JAK2、p-STAT3均上调，且差异有统计学意义（P＜0.05）；HBV-HCC组较HCC组及正常对照组JAK2、STAT3磷酸化水平均升高，差异有统计学意义（P＜0.05）；HepG2-HBx组中JAK2、p-JAK2、STAT3、p-STAT3蛋白表达水平均高于HepG2-vector对照组，差异有统计学意义（P＜0.05）；HepG2-HBx组较HepG2-vector组JAK2和STAT3磷酸化水平升高，差异有统计学意义（P＜0.05）。结论 HBV相关肝细胞癌患者HBx蛋白可能通过异常激活JAK2/STAT3信号通路而参与肿瘤的发生发展。
Abstract:
Objective To investigate the expression and mechanism of JAK2/STAT3 pathway in HBV-related hepatocellular carcinoma.Methods From February 2019 to April 2021, 15 patients with HBV-related hepatocellular carcinoma and 15 patients with non-HBV-related hepatocellular carcinoma were selected from Shanxi Provincial People’s Hospital. The expression of JAK2, p-JAK2, STAT3 and p-STAT3 protein in cancer tissues and adjacent tissues was detected by Western blot. The expression of JAK2, p-JAK2, STAT3 and p-STAT3 protein in HepG2 cell line stably expressing HBx was further detected.Results The expression levels of JAK2, p-JAK2, STAT3 and p-STAT3 proteins in cancer tissues of HBV-HCC group and HCC group were higher than those in adjacent tissues, and the differences were statistically significant (P<0.05). The expression of JAK2 and STAT3 protein in HBV-HCC group was higher than that in HCC group, but the difference was not statistically significant (P>0.05), while p-JAK2 and p-STAT3 were up-regulated, the difference was statistically significant (P<0.05). The phosphorylation levels of JAK2 and STAT3 in HBV-HCC group were significantly higher than those in HCC group and normal control group, and the difference was statistically significant (P<0.05). The protein expression levels of JAK2, p-JAK2, STAT3 and p-STAT3 in HepG2-HBx group were higher than those in HepG2-vector control group, and the difference was statistically significant (P<0.05). The phosphorylation levels of JAK2 and STAT3 in HepG2-HBx group were significantly higher than those in HepG2-vector group, and the difference was statistically significant (P<0.05).Conclusion HBx protein may be involved in the occurrence and development of HBV-related hepatocellular carcinoma by abnormally activating JAK2/STAT3 signaling pathway.

参考文献/References:

[1]Chen T,Pei J,Wang J,et al.HBx-related long non-coding RNA 01152 promotes cell proliferation and survival by IL-23 in hepatocellular carcinoma[J].Biomed Pharmacother,2019,115:108877.[2]Yen CJ,Yang ST,Chen RY,et al.Hepatitis B virus X protein (HBx) enhances centrosomal P4.1-associated protein (CPAP) expression to promote hepatocarcinogenesis[J].J Biomed Sci,2019,26(1):44.[3]Yang MH,Chen M,Mo HH,et al.Utilizing Experimental Mouse Model to Identify Effectors of Hepatocellular Carcinoma Induced by HBx Antigen[J].Cancers (Basel),2020,12(2):409.[4]Slagle BL,Bouchard MJ.Role of HBx in hepatitis B virus persistence and its therapeutic implications[J].Curr Opin Virol,2018,30:32-38.[5]Sivasudhan E,Blake N,Lu Z,et al.Hepatitis B Viral Protein HBx and the Molecular Mechanisms Modulating the Hallmarks of Hepatocellular Carcinoma: A Comprehensive Review[J].Cells,2022,11(4):741.[6]Huang FY,Wong DK,Mak LY,et al.Hepatitis B virus X protein promotes hepatocarcinogenesis via the activation of HMGA2/STC2 signaling to counteract oxidative stress-induced cell death[J].Carcinogenesis,2022,43(7):671-681.[7]Lee AR,Park YK,Dezhbord M,et al.Interaction between the Hepatitis B Virus and Cellular FLIP Variants in Viral Replication and the Innate Immune System[J].Viruses,2022,14(2):373.[8]Sartorius K,An P,Winkler C,et al.The Epigenetic Modulation of Cancer and Immune Pathways in Hepatitis B Virus-Associated Hepatocellular Carcinoma:The Influence of HBx and miRNA Dysregulation[J].Front Immunol,2021,12:661204.[9]Zeisel MB,Guerrieri F,Levrero M.Host Epigenetic Alterations and Hepatitis B Virus-Associated Hepatocellular Carcinoma[J].J Clin Med,2021,10(8):1715.[10]Zheng C,Liu M,Ge Y,et al.HBx increases chromatin accessibility and ETV4 expression to regulate dishevelled-2 and promote HCC progression[J].Cell Death Dis,2022,13(2):116.[11]Sartorius K,Swadling L,An P,et al.The Multiple Roles of Hepatitis B Virus X Protein (HBx) Dysregulated MicroRNA in Hepatitis B Virus-Associated Hepatocellular Carcinoma (HBV-HCC) and Immune Pathways[J].Viruses,2020,12(7):746.[12]Hin Tang JJ,Hao Thng DK,Lim JJ,et al.JAK/STAT signaling in hepatocellular carcinoma[J].Hepat Oncol,2020,7(1):HEP18.[13]Lee H,Jeong AJ,Ye SK.Highlighted STAT3 as a potential drug target for cancer therapy[J].BMB Rep,2019,52(7):415-423.[14]Shi SY,Luk CT,Schroer SA,et al.Janus Kinase 2 (JAK2) Dissociates Hepatosteatosis from Hepatocellular Carcinoma in Mice[J].J Biol Chem,2017,292(9):3789-3799.[15]Kim H,Kim D,Choi SA,et al.KDM3A histone demethylase functions as an essential factor for activation of JAK2-STAT3 signaling pathway[J].Proc Natl Acad Sci U S A,2018,115(46):11766-11771.[16]Zheng Y,Ming P,Zhu C,et al.Hepatitis B virus X protein-induced SH2 domain-containing 5 (SH2D5) expression promotes hepatoma cell growth via an SH2D5-transketolase interaction[J].J Biol Chem,2019,294(13):4815-4827.[17]Liu Y,Feng J,Sun M,et al.Long non-coding RNA HULC activates HBV by modulating HBx/STAT3/miR-539/APOBEC3B signaling in HBV-related hepatocellular carcinoma[J].Cancer Lett,2019,454:158-170.

相似文献/References:

[1]王利娜,赵雪梅,徐云霞,等.磁共振扩散张量成像在肝细胞癌及 肝转移瘤鉴别诊断价值研究[J].医学信息,2018,31(09):12.[doi:10.3969/j.issn.1006-1959.2018.09.004]
　WANG Li-na,ZHAO Xue-mei,XU Yun-xia,et al.Diagnostic Value of Magnetic Resonance Diffusion Tensor Imaging in Hepatocellular Carcinoma and Liver Metastases[J].Journal of Medical Information,2018,31(24):12.[doi:10.3969/j.issn.1006-1959.2018.09.004]
[2]刘 冰,杨 帅,费锡斌,等.GPC-3联合CK-19免疫组化检测在肝细胞癌诊断及鉴别诊断中的应用[J].医学信息,2019,32(23):169.[doi:10.3969/j.issn.1006-1959.2019.23.054]
　LIU Bing,YANG Shuai,FEI Xi-bin,et al.Application of GPC-3 Combined with CK-19 Immunohistochemical Detection in Diagnosis and Differential Diagnosis of Hepatocellular Carcinoma[J].Journal of Medical Information,2019,32(24):169.[doi:10.3969/j.issn.1006-1959.2019.23.054]
[3]李文华,许传斌,崔景景,等.基于治疗前MR-T2WI影像组学特征预测肝细胞癌射频消融术后早期复发的价值[J].医学信息,2022,35(18):39.[doi:10.3969/j.issn.1006-1959.2022.18.009]
　LI Wen-hua,XU Chuan-bin,CUI Jing-jing,et al.The Value of Predicting Early Recurrence of Hepatocellular Carcinoma After Radiofrequency Ablation Based on Pre-treatment MR-T2WI Radiomics Features[J].Journal of Medical Information,2022,35(24):39.[doi:10.3969/j.issn.1006-1959.2022.18.009]
[4]彭莉蓉,黎村艳,史 杨.肿瘤微环境免疫细胞中差异lncRNA对肝细胞癌预后的预测价值[J].医学信息,2022,35(20):18.[doi:10.3969/j.issn.1006-1959.2022.20.005]
　PENG Li-rong,LI Cun-yan,SHI Yang.The Predictive Value of Differential lncRNA in Tumor Microenvironment Immune Cells for the Prognosis of Hepatocellular Carcinoma[J].Journal of Medical Information,2022,35(24):18.[doi:10.3969/j.issn.1006-1959.2022.20.005]
[5]刘丽丽.CLCVP对肝细胞癌行腹腔镜肝叶切除手术相关指标及肝门阻断时间的影响[J].医学信息,2020,33(19):88.[doi:10.3969/j.issn.1006-1959.2020.19.025]
　LIU Li-li.The Effect of CLCVP on the Operation-related Indexes and Port Occlusion Time in Patients with Hepatocellular Carcinoma Undergoing Laparoscopic Lobectomy[J].Journal of Medical Information,2020,33(24):88.[doi:10.3969/j.issn.1006-1959.2020.19.025]
[6]杨孟涛,汪 艇,杜 伟,等.miR-181b-5p靶向调控SPP1在肝细胞癌中过表达的临床意义及作用机制[J].医学信息,2022,35(24):79.[doi:10.3969/j.issn.1006-1959.2022.24.016]
　YANG Meng-tao,WANG Ting,DU Wei,et al.Clinical Significance and Mechanism of miR-181b-5p Targeting to Regulate SPP1 Overexpression in Hepatocellular Carcinoma[J].Journal of Medical Information,2022,35(24):79.[doi:10.3969/j.issn.1006-1959.2022.24.016]
[7]孙莹莹,龚先琼.中药单体治疗肝细胞癌的研究[J].医学信息,2021,34(09):33.[doi:10.3969/j.issn.1006-1959.2021.09.008]
　SUN Ying-ying,GONG Xian-qiong.Study on the Treatment of Hepatocellular Carcinoma with Chinese Medicine Monomer[J].Journal of Medical Information,2021,34(24):33.[doi:10.3969/j.issn.1006-1959.2021.09.008]
[8]唐 菀,张晓珣,柴 进.SLCO1B1在肝细胞癌中的表达及其对患者预后的影响[J].医学信息,2023,36(02):12.[doi:10.3969/j.issn.1006-1959.2023.02.002]
　TANG Wan,ZHANG Xiao-xun,CHAI Jin.Expression of SLCO1B1 in Hepatocellular Carcinoma and its Effect on Prognosis[J].Journal of Medical Information,2023,36(24):12.[doi:10.3969/j.issn.1006-1959.2023.02.002]
[9]蒙建源,朱刚健.应用细胞免疫治疗肝细胞癌的研究[J].医学信息,2023,36(05):177.[doi:10.3969/j.issn.1006-1959.2023.05.037]
　MENG Jian-yuan,ZHU Gang-jian.Study on Cellular Immunotherapy for Hepatocellular Carcinoma[J].Journal of Medical Information,2023,36(24):177.[doi:10.3969/j.issn.1006-1959.2023.05.037]
[10]张 政,卢鸿健,李明慧,等.基于生物信息学分析肝细胞癌中lncRNA-miRNA-mRNA的调控网络[J].医学信息,2023,36(06):1.[doi:10.3969/j.issn.1006-1959.2023.06.001]
　ZHANG Zheng,LU Hong-jian,LI Ming-hui,et al.Analysis of lncRNA-miRNA-mRNA Regulatory Network in Hepatocellular Carcinoma Based on Bioinformatics[J].Journal of Medical Information,2023,36(24):1.[doi:10.3969/j.issn.1006-1959.2023.06.001]

更新日期/Last Update: 1900-01-01